Szymczyk, J. et al. identified that fibroblast growth factor 1 (FGF1) triggers the activation of AKT activation FGFR-overexpressed cancer cells, consequently affording protection against the effects of paclitaxel [96]. The gene discussed is FGF1; the disease is cancer.